ELM-2 trial: using ctDNA and MRD to measure odronextamab outcomes in DLBCL and FL Published 2024-02-05 Download video MP4 360p Download video MP4 720p Recommendations 02:26 Serum biomarkers as predictors of disease progression in smoldering myeloma 02:21 Unmet needs in LR-MDS: RBC transfusion-dependence 01:01 The current landscape of antibody-based therapies in R/R DLBCL 04:02 Testing for BCR::ABL kinase mutations in CML and how they impact TKi resistance 03:27 The mechanism of bispecific T-cell engagers in B-ALL: genomic alterations 09:48 Генерал КРИВОНОС: знаю правду про ВІДСТАВКУ ЗАЛУЖНОГО! Атакували неспроста. Повісять гучний провал 10:18 Pineapple express soaks Southern California - State of emergency issued 10:43 Is this the end of Google Search? How the giant could lose its lead 01:45 Using frailty to determine CAR-T eligibility in patients with R/R MM 10:39 Why Getting A Job Feels Impossible Right Now 04:00 Southern California braces for another intense storm 00:47 Screening for CHIP to detect potential TMNs in cancer treatment 00:53 Should patients with smoldering myeloma be treated outside of the clinical trial setting? 01:25 Low bone marrow cellularity predicts hematologic AEs to CPX-351 in AML 00:51 An update from ASH 2023: advancements in NHL treatment 01:43 Real-world outcomes of teclistamab for R/R MM 08:53 California Storm Watch: Power outages, wind gusts, rain and more - Feb. 4, 2024 02:50 Time to achieve platelet count response with efgartigimod in patients with persistent/chronic ITP 10:02 What is the Most Important Training Variable? 19:26 ABC World News Tonight Full Broadcast - Feb. 3, 2024 Similar videos 1:01:18 Update on Lymphoma from the 2022 American Society of Hematology ASH Annual Meeting | LRF Webinars More results